Return to site

Liberty Biopharma Appoints Peter Ashkin as Director

RICHMOND, BC / ACCESSWIRE / March 1, 2017 / The Board of Directors of Liberty Biopharma Inc. (TSX VENTURE: LTY) ("Liberty Biopharma" or "Company") today announced the appointment of veteran technology executive Peter Ashkin as an independent director. Mr. Ashkin's appointment expands the Board to five directors, three of whom are independent.

Mr. Ashkin will be a member of both the Company's Audit Committee and its Compensation and Corporate Governance Committee.

"We are delighted to welcome Mr. Ashkin to our Board of Directors," said Bohdan Romaniuk, Liberty Biopharma Chairman. "Peter has 35 years of experience in senior leadership positions in product development, operations and marketing spanning some of the most dynamic and innovative sectors of the Internet, high tech and communications and media industries. His knowledge and hands-on experience in mentoring and nurturing high tech and biotech startups will also prove to be invaluable. We very much look forward to working closely with Peter and to benefitting from his judgment, counsel and entrepreneurial focus as Liberty transitions to the next stage of its commercial and business development."

Mr. Ashkin is Managing Partner of Baker, Cook and Constable LLC, a venture capital firm that focuses on investing in, and operating high-tech start-up companies. He is also President of Peter Ashkin Consulting, a consulting agency that focuses on high-tech start-ups. Previously, Mr. Ashkin served as President of the Technology Group for CanWest Mediaworks (2004 - 2006), at that time, Canada's largest media company, publishing newspapers and delivering broadcast television and cable services in multiple locations across the country. Before joining CanWest, Mr. Ashkin served as President of Product Strategy for AOL (America Online) (2001 - 2004), at that time, the world's largest Internet provider. Mr. Ashkin also served as Senior Vice President and Chief Technology Officer of Gateway Computer (1998 - 2001) and prior thereto served in a number of senior and executive management positions at both Toshiba Corporation (NASDAQ:TOSBF) and Apple Inc. (NASDAQ:AAPL).

Mr. Ashkin is a Director and Chairman of the Compensation Committee for Sphere 3D Corp. (NASDAQ:ANY) and also serves on the Boards of several private technology companies. He is a graduate of the Massachusetts Institute of Technology where he studied electrical engineering.

"I'm very excited about the opportunity to assist Liberty Biopharma in its efforts to become a global leader in stem cell therapy. The future of regenerative medicine lies in providing patients with safe, convenient, and rapid delivery of gold standard stem cell therapies for a variety of medical indications." said Mr. Ashkin.

The appointment is subject to regulatory approval including that of the TSX Venture Exchange.

About Liberty Biopharma Inc.

Liberty Biopharma is a clinical stage biopharmaceutical company developing and commercializing regenerative stem cell technologies and therapeutic solutions for independence and quality of life. Our focus is on significant areas of unmet clinical need, such as wound management, osteoarthritis, musculoskeletal injury, cardiovascular diseases, and autoimmune diseases.


Cautionary Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "likely," "estimated," and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that Liberty Biopharma may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Liberty Biopharma. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and Liberty Biopharma is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

For further information, please contact:

Liberty Biopharma Inc.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 604-377-7575

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

All Posts

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly